Actinium-225 Alpha Therapy: Next-Generation

What Makes Actinium-225 Different From Lutetium-177?

Targeted radiopharmaceutical therapy delivers a cytotoxic radioisotope directly to tumor cells using a targeting ligand. Lutetium-177 vipivotide tetraxetan, marketed by Novartis as Pluvicto, was approved by the U.S. Food and Drug Administration in 2022 for metastatic castration-resistant prostate cancer expressing prostate-specific membrane antigen (PSMA). Lu-177 emits beta particles, which travel up to a few millimeters in tissue and produce sparse ionization along their track.

Actinium-225 belongs to a fundamentally different class of emitters. Its decay chain produces four alpha particles, each carrying far more energy than a beta particle but depositing it within a much shorter range — typically only a few cell diameters. This high linear energy transfer creates dense, often irreparable double-strand DNA breaks, which researchers believe could overcome resistance mechanisms that limit Lu-177 efficacy, particularly in tumors with heterogeneous PSMA expression or extensive bone marrow involvement.

What Does the Clinical Evidence Show So Far?

Researchers at the University Hospital Heidelberg, led by Clemens Kratochwil and colleagues, published an early case series in the Journal of Nuclear Medicine describing the use of Ac-225-PSMA-617 in patients with metastatic castration-resistant prostate cancer who had exhausted standard therapies, including Lu-177-PSMA. The reports described substantial reductions in prostate-specific antigen levels and radiographic responses in some patients, although xerostomia, or dry mouth, emerged as a dose-limiting toxicity due to PSMA expression in the salivary glands.

Several pharmaceutical companies, including Novartis, Bayer, and a number of smaller radiopharmaceutical developers, have advanced Ac-225-based candidates into formal clinical programs. Phase 1 and phase 2 studies are evaluating dosing strategies, fractionation schedules, and combination approaches with androgen receptor pathway inhibitors. Larger randomized trials will be needed before Ac-225 therapies can be compared head-to-head against the current standard of care.

Why Is Global Supply a Limiting Factor?

Historically, the world's supply of Ac-225 has been generated almost entirely from the decay of thorium-229 stockpiles held at a small number of facilities, including Oak Ridge National Laboratory in the United States and the Joint Research Centre in Karlsruhe, Germany. Annual global production from these legacy sources is measured in only a few curies — far below what would be required to treat the patient populations that current trials are targeting.

To address this gap, national laboratories and private companies are investing in accelerator-based production routes, including high-energy proton irradiation of thorium-232 and dedicated cyclotron methods. Organizations such as the U.S. Department of Energy and the International Atomic Energy Agency have flagged isotope supply as a strategic priority. Until production scales meaningfully, access to Ac-225 therapies is expected to be concentrated at specialized academic and integrated theranostic centers.